Paul Mattis's questions to ACADIA Pharmaceuticals Inc (ACAD) leadership • Q3 2024
Question
An analyst on behalf of Paul Mattis of Stifel asked about the expected return on investment (ROI) for the NUPLAZID direct-to-consumer (DTC) campaign in 2025, given the strong execution in 2024.
Answer
Executive Brendan Teehan stated that since the campaign began in mid-August, the vast majority of its benefits will be realized starting in 2025. He emphasized that the lifetime value of a NUPLAZID patient extends beyond 2025, so the full ROI will not be realized in a single year. While enthusiastic about early indicators like website visits, the primary impact on new patient starts and their continuing value will be seen in 2025 and beyond.